Log in
NASDAQ:TTPH

Tetraphase Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.20
0.00 (0.00 %)
(As of 07/28/2020)
Add
Compare
Today's Range
$2.18
Now: $2.20
$2.27
50-Day Range
$2.20
MA: $2.20
$2.20
52-Week Range
$0.56
Now: $2.20
$8.60
Volume282,689 shs
Average Volume932,542 shs
Market Capitalization$15.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Read More
Tetraphase Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.92 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600
Employees119

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.38 million
Book Value$6.68 per share

Profitability

Net Income$-70,080,000.00
Net Margins-798.18%

Miscellaneous

Market Cap$15.98 million
Next Earnings DateN/A
OptionableOptionable

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Tetraphase Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tetraphase Pharmaceuticals
.

What stocks does MarketBeat like better than Tetraphase Pharmaceuticals?

Wall Street analysts have given Tetraphase Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tetraphase Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.63) by $0.32. The biopharmaceutical company earned $1.76 million during the quarter, compared to analyst estimates of $2.45 million. Tetraphase Pharmaceuticals had a negative return on equity of 210.86% and a negative net margin of 798.18%.
View Tetraphase Pharmaceuticals' earnings history
.

When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work?

Tetraphase Pharmaceuticals shares reverse split before market open on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of Tetraphase Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

Who are some of Tetraphase Pharmaceuticals' key competitors?

What other stocks do shareholders of Tetraphase Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), OPKO Health (OPK), Novavax (NVAX), Bank of America (BAC), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO) and Synergy Pharmaceuticals (SGYP).

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the following people:
  • Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)
  • Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)
  • Dr. Jacques Dumas, Chief Scientific Officer (Age 53)
  • Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)
  • Mr. Larry G. Edwards, Chief Operating Officer (Age 47)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

What is Tetraphase Pharmaceuticals' stock price today?

One share of TTPH stock can currently be purchased for approximately $2.20.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $15.98 million and generates $7.38 million in revenue each year. The biopharmaceutical company earns $-70,080,000.00 in net income (profit) each year or ($22.85) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe.

What is Tetraphase Pharmaceuticals' official website?

The official website for Tetraphase Pharmaceuticals is www.tphase.com.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL WAY, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.